These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 23460322)

  • 1. Biopsy validation of 18F-DOPA PET and biodistribution in gliomas for neurosurgical planning and radiotherapy target delineation: results of a prospective pilot study.
    Pafundi DH; Laack NN; Youland RS; Parney IF; Lowe VJ; Giannini C; Kemp BJ; Grams MP; Morris JM; Hoover JM; Hu LS; Sarkaria JN; Brinkmann DH
    Neuro Oncol; 2013 Aug; 15(8):1058-67. PubMed ID: 23460322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective trial evaluating the sensitivity and specificity of 3,4-dihydroxy-6-[18F]-fluoro-L-phenylalanine (18F-DOPA) PET and MRI in patients with recurrent gliomas.
    Youland RS; Pafundi DH; Brinkmann DH; Lowe VJ; Morris JM; Kemp BJ; Hunt CH; Giannini C; Parney IF; Laack NN
    J Neurooncol; 2018 May; 137(3):583-591. PubMed ID: 29330751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the amino acid tracers 18F-FET and 18F-DOPA in high-grade glioma patients.
    Lapa C; Linsenmann T; Monoranu CM; Samnick S; Buck AK; Bluemel C; Czernin J; Kessler AF; Homola GA; Ernestus RI; Löhr M; Herrmann K
    J Nucl Med; 2014 Oct; 55(10):1611-6. PubMed ID: 25125481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Value of 18F-3,4-dihydroxyphenylalanine PET/MR image fusion in pediatric supratentorial infiltrative astrocytomas: a prospective pilot study.
    Morana G; Piccardo A; Milanaccio C; Puntoni M; Nozza P; Cama A; Zefiro D; Cabria M; Rossi A; Garrè ML
    J Nucl Med; 2014 May; 55(5):718-23. PubMed ID: 24652828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 11C-CHO PET in optimization of target volume delineation and treatment regimens in postoperative radiotherapy for brain gliomas.
    Li FM; Nie Q; Wang RM; Chang SM; Zhao WR; Zhu Q; Liang YK; Yang P; Zhang J; Jia HW; Fang HH
    Nucl Med Biol; 2012 Apr; 39(3):437-42. PubMed ID: 22172386
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-grade glioma radiation therapy target volumes and patterns of failure obtained from magnetic resonance imaging and 18F-FDOPA positron emission tomography delineations from multiple observers.
    Kosztyla R; Chan EK; Hsu F; Wilson D; Ma R; Cheung A; Zhang S; Moiseenko V; Benard F; Nichol A
    Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):1100-6. PubMed ID: 24161427
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [F-DOPA PET/MR based target definiton in the 3D based radiotherapy treatment of glioblastoma multiforme patients. First Hungarian experiences].
    Sipos D; Tóth Z; Lukács G; Bajzik G; Hadjiev J; Cselik Z; Repa I; Kovács Á
    Ideggyogy Sz; 2019 May; 72(5-6):209-215. PubMed ID: 31241266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation of 6-18F-fluoro-L-dopa PET uptake with proliferation and tumor grade in newly diagnosed and recurrent gliomas.
    Fueger BJ; Czernin J; Cloughesy T; Silverman DH; Geist CL; Walter MA; Schiepers C; Nghiemphu P; Lai A; Phelps ME; Chen W
    J Nucl Med; 2010 Oct; 51(10):1532-8. PubMed ID: 20847166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of trans-1-amino-3-18F-fluorocyclobutanecarboxylic acid accumulation in low-grade glioma in chemically induced rat models: PET and autoradiography compared with morphological images and histopathological findings.
    Doi Y; Kanagawa M; Maya Y; Tanaka A; Oka S; Nakata N; Toyama M; Matsumoto H; Shirakami Y
    Nucl Med Biol; 2015 Aug; 42(8):664-72. PubMed ID: 26022202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radiation treatment planning in brain tumours: potential impact of 3-O-methyl-6-[(18)F]fluoro-L-DOPA and PET.
    Alheit H; Oehme L; Winkler C; Füchtner F; Hoepping A; Grabowski J; Kotzerke J; Beuthien-Baumann B
    Nuklearmedizin; 2008; 47(5):200-4. PubMed ID: 18852926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combining
    Girard A; Le Reste PJ; Metais A; Carsin Nicol B; Chiforeanu DC; Bannier E; Campillo-Gimenez B; Devillers A; Palard-Novello X; Le Jeune F
    J Neurooncol; 2021 Dec; 155(3):287-295. PubMed ID: 34686993
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simultaneous FET-PET and contrast-enhanced MRI based on hybrid PET/MR improves delineation of tumor spatial biodistribution in gliomas: a biopsy validation study.
    Song S; Cheng Y; Ma J; Wang L; Dong C; Wei Y; Xu G; An Y; Qi Z; Lin Q; Lu J
    Eur J Nucl Med Mol Imaging; 2020 Jun; 47(6):1458-1467. PubMed ID: 31919633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic value of fusion of metabolic and structural images for stereotactic biopsy of brain tumors without enhancement after contrast medium injection.
    Todeschi J; Bund C; Cebula H; Chibbaro S; Lhermitte B; Pin Y; Lefebvre F; Namer IJ; Proust F
    Neurochirurgie; 2019 Dec; 65(6):357-364. PubMed ID: 31560911
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A surgical strategy using a fusion image constructed from 11C-methionine PET, 18F-FDG-PET and MRI for glioma with no or minimum contrast enhancement.
    Ideguchi M; Nishizaki T; Ikeda N; Okamura T; Tanaka Y; Fujii N; Ohno M; Shimabukuro T; Kimura T; Ikeda E; Suga K
    J Neurooncol; 2018 Jul; 138(3):537-548. PubMed ID: 29516344
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of multiparametric 18F-fluoro-L-3,4-dihydroxy-phenylalanine PET/MRI in post-therapy assessment of patients with gliomas.
    Fraioli F; Shankar A; Hyare H; Ferrazzoli V; Militano V; Samandouras G; Mankad K; Solda F; Zaccagna F; Mehdi E; Lyasheva M; Bomanji J; Novruzov F
    Nucl Med Commun; 2020 Jun; 41(6):517-525. PubMed ID: 32282634
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose-painted volumetric modulated arc therapy of high-grade glioma using 3,4-dihydroxy-6-[
    Kosztyla R; Raman S; Moiseenko V; Reinsberg SA; Toyota B; Nichol A
    Br J Radiol; 2019 Jul; 92(1099):20180901. PubMed ID: 31017449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. (18)F-Fluorothymidine PET-CT for resected malignant gliomas before radiotherapy: tumor extent according to proliferative activity compared with MRI.
    Zhao F; Li M; Wang Z; Fu Z; Cui Y; Chen Z; Yu J
    PLoS One; 2015; 10(3):e0118769. PubMed ID: 25738617
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Patel CB; Fazzari E; Chakhoyan A; Yao J; Raymond C; Nguyen H; Manoukian J; Nguyen N; Pope W; Cloughesy TF; Nghiemphu PL; Czernin J; Lai A; Ellingson BM
    J Neurooncol; 2018 Sep; 139(2):399-409. PubMed ID: 29679199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [18F]-fluoro-ethyl-L-tyrosine PET: a valuable diagnostic tool in neuro-oncology, but not all that glitters is glioma.
    Hutterer M; Nowosielski M; Putzer D; Jansen NL; Seiz M; Schocke M; McCoy M; Göbel G; la Fougère C; Virgolini IJ; Trinka E; Jacobs AH; Stockhammer G
    Neuro Oncol; 2013 Mar; 15(3):341-51. PubMed ID: 23335162
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of LAT1 in (18)F-DOPA uptake in malignant gliomas.
    Youland RS; Kitange GJ; Peterson TE; Pafundi DH; Ramiscal JA; Pokorny JL; Giannini C; Laack NN; Parney IF; Lowe VJ; Brinkmann DH; Sarkaria JN
    J Neurooncol; 2013 Jan; 111(1):11-8. PubMed ID: 23086431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.